FDA declines to define ‘natural’
In a much anticipated letter response, the Food and Drug Administration (FDA) has officially declined the opportunity to administratively determine whether foods containing bio-engineered ingredients may be labelled as ‘natural’, ‘all natural’ or ‘100 per cent natural’ and, more generally, declined the opportunity to define ‘natural’ in the context of food labelling.
The issue stems from an influx of litigation involving the alleged false advertising of food products making a variety of ‘natural’ claims, where no official federal law, rule or regulation defines the term ‘natural’. Three separate US.S District Court cases — Cox v Gruma Corp (ND Cal), Barnes v Campbell Soup Co (ND Cal) and In re General Mills Inc Kix Cereal Litigation (DNJ) — referred the issue to the FDA on primary jurisdiction grounds for the FDA’s determination as to whether food products containing corn from genetically modified seeds could be labelled ‘natural’.
As stated in the FDA’s 6 January letter, despite significant push from industry and consumer groups alike, FDA declined to allocate its resources ‘at this time’ to make a determination regarding whether and under what circumstances food products containing genetically engineered ingredients may be labelled ‘natural’…
If you are registered and logged in to the site, click on the link below to read the rest of the DLA Piper briefing. If not, please register or sign in with your details below.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from DLA Piper
News from The Lawyer
Briefings from DLA Piper
Health Alert — Julia Clare v Australian Community Pharmacy Authority; Dr Reid v Medical Council of NSW; and more
DLA Piper has released the 22 December 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
The European Court of Justice (CJEU) has handed down a landmark judgment concerning the patentability of stem cells in Europe.
Analysis from The Lawyer
Regulators are ramping up the pressure in the aftermath of recession, leaving firms to compete for compliance and restructuring work
Shearman & Sterling is making its presence felt in the City, squaring up to magic circle firms and looking to muscle in on key relationships. Private equity house Bridgepoint is one outfit that has had its head turned by the US firm.